ライフサイエンスコーパス: HAART

1 HAART is very effective in suppressing HIV-1 replication

2 HAART receipt during pregnancy was associated with incre

3 HAART reduces but does not eliminate the risk of ARR.

4 HAART-treated adults with wild-type HIV were prospective

5 sed children to 860 echocardiograms from 140 HAART-unexposed but HIV-infected children from the Pulmo

6 The CHAART-2 (HAART-Associated Cardiotoxicity in HIV-Infected Children

7 ctively compared 148 echocardiograms from 74 HAART-exposed children to 860 echocardiograms from 140 H

8 ARV prophylaxis (prenatal zidovudine, 43.9%; HAART, 52.1%).

9 After HAART availability, non-infectious lung diseases were no

10 After HAART introduction , influenza-related mortality in adul

11 e interval [CI], 2.2-2.7; p<0.001) and after HAART availability (MACS, adjusted-OR, 1.5; 95%CI 1.3-1.

12 e severity of HIV infection before and after HAART.

13 gatibacter was significantly decreased after HAART.

14 immunoblastic histology has decreased after HAART.

15 over the six-month study period, even after HAART.

16 nses continue to shape HIV-1 evolution after HAART initiation, but the extent and rate at which this

17 icatella, and Atopobium were increased after HAART.

18 HLA-associated evolution in HIV-1 Pol after HAART initiation in a large, population-based observatio

19 Immune reconstitution after HAART initiation did not restore protective levels of me

20 ART era and evaluated mortality trends after HAART introduction in the United States.

21 had no detectable viremia for 9 years after HAART cessation.

22 otherapy in a group of grass pollen-allergic HAART-treated HIV-positive patients.

23 z-score for difference = 1.07; p = 0.02) and HAART exposure duration (z-score difference per year = 0

24 adjusted hazard, 0.34; 95% CI, .23, .49) and HAART (0.39 [0.31, 0.48]) decreased the hazard of all-ca

25 Comparing the HAART-exposed and HAART-unexposed groups, any HAART exposure was positivel

26 rates of HBV infection in the pre-HAART and HAART eras and to identify factors associated with incid

27 le response in the coinfected, non-HAART and HAART groups were 2.1 (95% confidence interval [CI], 1.7

28 We studied the impact of HIV and HAART on ARR among patients taking thrice-weekly antitub

29 of this study suggest that HIV infection and HAART can have significant effects on salivary microbial

30 iduals in both the pre-HAART (MACS only) and HAART eras; and adjusted Cox proportional hazard ratios

31 While both OST and HAART are life-saving treatments, joint administration i

32 Both OST and HAART independently protected against HIV-related death,

33 the independent and joint effects of OST and HAART on all-cause as well as drug- and HIV-related mort

34 the independent and joint effects of OST and HAART on mortality, by cause, within a population of HIV

35 components of highly active antiretroviral (HAART) therapy targeting HIV reverse transcriptase (RT).

36 AART-exposed and HAART-unexposed groups, any HAART exposure was positively associated with left ventr

37 LV mass was negatively associated with any HAART exposure (z-score difference = -0.64; p = 0.01) as

38 This study suggests that highly active ART (HAART) does not appear to impair heart function.

39 related exposures (ART or highly active ART [HAART], HIV-RNA plasma viral load [PVL], and nadir or cu

40 ed children were measles IgG seropositive at HAART initiation.

41 In the United States before HAART, influenza-related mortality rates in adults with

42 gible if they had an HIV diagnosis and began HAART between January 1, 1996 and June 30, 2010.

43 Associations between HAART exposure and echocardiographic measures were evalu

44 sults imply that the effect of baseline BMI, HAART initiation, baseline viral load, and the number of

45 protection (IRR, 0.2 [CI, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or g

46 ered by known atherogenic effects of chronic HAART or the prolonged inflammatory state associated wit

47 British Columbia HAART Observational, Medical Evaluation and Research coh

48 responses to long-term lamivudine-containing HAART were comparable between HIV-infected patients with

49 l other HIV-infected women, those continuing HAART from before pregnancy had higher odds of PTD (adju

50 LIT therapy in viro-immunological controlled HAART treated HIV positive patients was efficacious, saf

51 main common in HIV-infected persons, despite HAART, but whether anemia predicts HAND in the HAART era

52 -associated HIV-1 evolution continues during HAART to an extent that is inversely related to the viro

53 s were observed in 269 (43%) patients during HAART and occurred at 49 of 63 (78%) investigated immune

54 copies/mL at an arbitrary time point during HAART (= T0), according to whether the actual, unreporte

55 eservoirs and reduce residual viremia during HAART.

56 enefit from focused efforts to promote early HAART initiation and adherence.

57 Effective HAART is associated with lower incidence of HBV infectio

58 d represent a secondary benefit of effective HAART.

59 urteen patients had been receiving effective HAART for at least 6 months (median, 1 year).

60 To achieve eradication, HAART must be combined with drugs that reactivate the do

61 Reversion of escape mutations following HAART initiation was extremely rare.

62 changes with immune reconstitution following HAART is unknown.

63 investigated immune reconstitution following HAART.

64 oinfected VATS subjects, after adjusting for HAART status, HIV RNA level, and CD4 cell count at basel

65 itive during pregnancy were not assessed for HAART eligibility during pregnancy or in the first four

66 attended an HIV clinic and been assessed for HAART eligibility.

67 ty-three HIV-1-infected patients, naive from HAART, were randomly assigned to HAART with dietary inte

68 The analysis examined the survival from HAART initiation to all-cause mortality or an AIDS event

69 sociated with hepatitis B e antigen (HBeAg), HAART <2 years, CD4 <200 cells/mm(3), detectable HIV RNA

70 However, HAART targets only actively replicating virus and is una

71 virus-induced uveitis should be suspected in HAART-naive, HIV-positive patients or in those in whom t

72 ea often has noninfectious causes, including HAART-related adverse events and HIV enteropathy.

73 A total of 13.1% of women who initiated HAART during pregnancy had detectable VL at delivery.

74 Initiating HAART at the antenatal clinic, improved counselling and

75 months in 3418 patients with HIV initiating HAART between November 2006 and November 2008 in 7 clini

76 a population of HIV-positive PWID initiating HAART.

77 epatomegaly were associated with no maternal HAART versus those with HAART (41% vs 6%; P < .05).

78 Prenatal maternal HAART was defined as triple antiretroviral therapy (ART)

79 neurocognitive impairment in a multicenter, HAART-era HIV cohort study (N = 1261), adjusting for pot

80 unfavorable response in the coinfected, non-HAART and HAART groups were 2.1 (95% confidence interval

81 -)TB(+)), 212 HIV patients not on HAART (non-HAART), and 116 HIV-infected patients on HAART.

82 of AIDS patients and 29% (95% CI, 22, 38) of HAART subjects and 3% (95% CI, 0.8, 7.2) and 42% (95% CI

83 After the administration of HAART, the intraocular inflammation disappeared entirely

84 Since the advent of HAART, patients with HIV infection have seen a significa

85 itiating virus replication upon cessation of HAART, thus leading to viral rebound.

86 the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient commu

87 n has not been established in the context of HAART.

88 Duration of HAART exposure was negatively associated with LV end-sys

89 ameters narrowed with increasing duration of HAART, independently of age (167.83 microm <3 years of H

90 was conducted to characterize the effects of HAART and revaccination on measles immunoglobulin G (IgG

91 identify long-term cardiovascular effects of HAART in HIV-infected children.

92 analysis demonstrated beneficial effects of HAART on cervical SIL in HIV-positive women.

93 The increasing efficiency of HAART has helped to transform HIV/AIDS into a chronic di

94 In the era of HAART, diarrhea from opportunistic infections is uncommo

95 The goal of HAART may need to be revised to a lower cutoff than 50 c

96 of diagnosis, late diagnosis, and history of HAART.

97 mmune reconstitution following initiation of HAART (P=.003).

98 gh school diploma; P = 0.013), initiation of HAART in the third trimester (23.9% vs. 12.3% and 8.6% i

99 Whereas early initiation of HAART should improve immunosurveillance and reduce the i

100 Interruption of HAART leads to a rapid rebound of viremia, so life-long

101 spiratory diseases after the introduction of HAART, and infectious respiratory diseases were associat

102 stand the potential pathogenic mechanisms of HAART-associated NeuroAIDS and design effective adjuvant

103 s aged 9-14 years, with at least 6 months of HAART, and a comparator group of healthy HIV-uninfected

104 ions in semen in the absence and presence of HAART, and suggest further studies.

105 HAART) (interval X) and between the start of HAART and the most recent WIHS visit (interval Y), and e

106 Despite the success of HAART in reducing mortality, resistant strains continue

107 Despite the overall success of HAART in slowing the progression to AIDS in HIV-infected

108 Even with the success of HAART, new drugs with novel mechanisms are needed to com

109 and lead to discontinuation or switching of HAART regimens.

110 However, there is no fundamental theory of HAART.

111 The timing of HAART initiation and prenatal care, along with medicatio

112 ependently of age (167.83 microm <3 years of HAART vs. 158.89 microm >6 years, p-trend = 0.02), and w

113 findings over 2 years in HIV+ adolescents on HAART in a prospective cohort, the Cape Town Adolescent

114 over time in perinatally HIV+ adolescents on HAART.

115 oviral therapy (HAART), 21% were formerly on HAART, and 24% were HAART-naive.

116 oup 1 (G1) consisted of patients with HIV on HAART (n = 176), Group 2 (G2) consisted of patients with

117 on HAART (32.6%) than those patients not on HAART (17.9%) (p<0.05).

118 nsisted of patients with HIV who were not on HAART (n = 48), and Group 3 (G3) consisted of controls w

119 ients (HIV(-)TB(+)), 212 HIV patients not on HAART (non-HAART), and 116 HIV-infected patients on HAAR

120 ients without HIV or with HIV who are not on HAART.

121 r manifestation was higher among patients on HAART (32.6%) than those patients not on HAART (17.9%) (

122 e reconstitution in HIV-infected patients on HAART for 12 months was poor despite a marked reduction

123 non-HAART), and 116 HIV-infected patients on HAART.

124 the response of CD8+ cells from patients on HAART.

125 c T lymphocytes (CTLs) from most patients on HAART.

126 they are subject to high FRR in subjects on HAART or with AIDS.

127 Those on HAART and protease inhibitor (PI)-based treatment had si

128 , and Thailand, the majority of whom were on HAART at study entry, were prospectively followed semian

129 h HIV regardless of whether patients were on HAART.

130 a HIV viral load >10,000 copies/mL while on HAART (p = 0.05).

131 After 1 year on HAART, HIV BAL contained an increased abundance of Prevo

132 dietary intervention (diet group, n = 43) or HAART without dietary intervention (control group, n = 4

133 Among HIV-positive participants, HAART increased the likelihood of regression (from prese

134 % changes in nadir CD4(+) T-cell percentage, HAART was not associated with measles IgG seroconversion

135 tal CMV rates did not differ by time period, HAART use, or infant HIV infection status.

136 CMV among HIV-exposed infants pre- and post- HAART.

137 l lymphomas (AR-DLBCLs) in the pre- and post-HAART era.

138 lated and compared between the pre- and post-HAART era.

139 were compared between the pre-HAART and post-HAART era.

140 ongenital CMV rates did not change, the post-HAART era showed reduced P/EP CMV and occurrence of rela

141 IV patients who underwent biopsy in the post-HAART era was 225 days (90-2446).

142 lysis was performed for patients in the post-HAART era.

143 ss rate was significantly higher in the post-HAART than the pre-HAART era (97.5% vs 91.9%, p=0.047).

144 e antiretroviral therapy (HAART) versus post-HAART era via meta-analysis.

145 ore incident respiratory infections both pre-HAART (MACS, odds ratio [adjusted-OR], 2.4; 95% confiden

146 infected vs. HIV-uninfected participants pre-HAART (hazard ratio [adjusted-HR] 2.9; 95%CI, 1.02-8.4;

147 o HIV-uninfected individuals in both the pre-HAART (MACS only) and HAART eras; and adjusted Cox propo

148 incidence rates of HBV infection in the pre-HAART and HAART eras and to identify factors associated

149 Outcomes were compared between the pre-HAART and post-HAART era.

150 cantly higher in the post-HAART than the pre-HAART era (97.5% vs 91.9%, p=0.047).

151 antly lower in the HAART era than in the pre-HAART era among HIV-infected (IRR, 0.2 [CI, 0.1 to 0.4])

152 outh Africa and the United States in the pre-HAART era and evaluated mortality trends after HAART int

153 an in those of similar children from the pre-HAART era but did decline over time.

154 ng ocular complication compared with the pre-HAART era.

155 ate is reduced from that observed in the pre-HAART era.

156 ilar to that in the United States in the pre-HAART era.

157 tiating antiretroviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odd

158 ndings underscore the importance of prenatal HAART for all HIV-infected pregnant women.

159 ere observed in the percentage of prescribed HAART, the percentage who achieved a suppressed HIV VL,

160 less than 200/muL, and 92 patients received HAART during chemotherapy.

161 CONCLUSION In adults receiving HAART, use of high-dose multivitamin supplements compare

162 ents with lung cancer who are also receiving HAART.

163 isolated from infected individuals receiving HAART and were found to exhibit potent induction activit

164 fected children 2 to <19 years old receiving HAART and with HIV loads <30,000 copies/mL, CD4% >/=15,

165 had >200 CD4 T cells/muL; 98% were receiving HAART at baseline.

166 Twenty-six patients were receiving HAART; viral load was <100 copies per mL in 12 patients.

167 In multivariate regression, HAART and PI use were positively associated with Lp-PLA2

168 t HIV progression by 6 months after starting HAART.

169 ferences remain up to 3 years after starting HAART.

170 n individuals with high discordancy starting HAART, but there was no association with subsequent HIV

171 Long-term HAART appears to be cardioprotective for HIV-infected ch

172 However, patients staying on long-term HAART still develop various HIV-associated neurological

173 chronic, untreated HIV-1 infection and that HAART had a restorative effect on this subset.

174 terested in the alternative possibility that HAART critically contributes to the neuroinflammation in

175 Our results suggest that HAART restores a normal frequency of CD8(+) T(SCM) and t

176 Comparing the HAART-exposed and HAART-unexposed groups, any HAART expo

177 In both cohorts during the HAART era, median ages at time of non-AIDS-related death

178 nfected persons with lung disease during the HAART era.

179 therapy (HAART) (before 1996) to 53% in the HAART era (P < 0.01); the median age of persons who died

180 d red blood cell indices predict HAND in the HAART era and may contribute to risk assessment.

181 of death in people diagnosed with HIV in the HAART era compared with the general population.

182 ART, but whether anemia predicts HAND in the HAART era is unknown.

183 to 2.4]) and was significantly lower in the HAART era than in the pre-HAART era among HIV-infected (

184 HIV-infected participants in the HAART era with respiratory infections had an increased r

185 at risk for developing CMV retinitis in the HAART era, although the incidence rate is reduced from t

186 incidence has decreased substantially in the HAART era, cytomegalovirus (CMV) retinitis remains an im

187 dence of HBV infection; however, even in the HAART era, incidence of HBV infection remains high among

188 tality among HIV-positive individuals in the HAART era, independent of study cohort.

189 In the HAART era, systemic anti-CMV therapy, while there is imm

190 lammation and lung complications seen in the HAART era.

191 During 11 years of follow-up, in the HAART-exposed group, LV mass and LV end-diastolic septal

192 shortening were higher when compared to the HAART-unexposed group.

193 pite highly active antiretroviral therapies (HAART) and can negatively affect patient quality of life

194 ion of highly active antiretroviral therapy (HAART) (before 1996) to 53% in the HAART era (P < 0.01);

195 art of highly active antiretroviral therapy (HAART) (interval X) and between the start of HAART and t

196 eiving highly active antiretroviral therapy (HAART) (median duration, 58 months), their median CD4 co

197 cts on highly active antiretroviral therapy (HAART) (n = 134) and subjects with low CD4 counts (AIDS

198 after highly active antiretroviral therapy (HAART) and 10 non-HIV-infected control individuals.

199 ths of highly active antiretroviral therapy (HAART) and 2 lines of conventional chemotherapy (pegylat

200 arting highly active antiretroviral therapy (HAART) and compared with 22 uninfected control subjects.

201 ty for highly active antiretroviral therapy (HAART) and reasons for lack of attendance.

202 under highly active antiretroviral therapy (HAART) and their association with cluster of differentia

203 Highly active antiretroviral therapy (HAART) decreases plasma viremia below the limits of dete

204 luding Highly Active Antiretroviral Therapy (HAART) drug regimens is widely considered to be one of t

205 in the highly active antiretroviral therapy (HAART) era approaches that of the general population whe

206 in the highly active antiretroviral therapy (HAART) era, needs evaluation.

207 d post-highly active antiretroviral therapy (HAART) era.

208 es and highly active antiretroviral therapy (HAART) exert strong selective pressures on human immunod

209 ion of highly active antiretroviral therapy (HAART) for prevention of mother-to-child transmission of

210 nts of highly active antiretroviral therapy (HAART) for the treatment of HIV-1.

211 HIV on highly active antiretroviral therapy (HAART) had any difference in their IOP compared with pat

212 though highly active antiretroviral therapy (HAART) has converted HIV into a chronic disease, a reser

213 Highly active antiretroviral therapy (HAART) has dramatically decreased mortality from HIV-1 i

214 ecade, highly active antiretroviral therapy (HAART) has improved the immune function and life expecta

215 Though highly active antiretroviral therapy (HAART) has led to better long-term outcomes in HIV infec

216 Highly-active antiretroviral therapy (HAART) has led to some reduction in influenza-related co

217 nts on highly active antiretroviral therapy (HAART) have a high risk of developing hypertension and d

218 ion of highly active antiretroviral therapy (HAART) in 1996.

219 ternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited se

220 -based highly active antiretroviral therapy (HAART) including efavirenz is recommended as a 1(st)-lin

221 Highly active antiretroviral therapy (HAART) is able to suppress human immunodeficiency virus

222 While highly active antiretroviral therapy (HAART) is successful in controlling the replication of H

223 era of highly active antiretroviral therapy (HAART) is unclear.

224 IV and highly active antiretroviral therapy (HAART) on HPV persistence and cervical squamous intraepi

225 ect of highly active antiretroviral therapy (HAART) on incident HBV infection in HIV-infected and HIV

226 ect of highly active antiretroviral therapy (HAART) on the incidence of herpes zoster (HZ) in human i

227 Highly active antiretroviral therapy (HAART) suppresses HIV-1 replication but cannot eliminate

228 Highly active antiretroviral therapy (HAART) suppresses HIV-1 replication, transforming the ou

229 he pre-highly active antiretroviral therapy (HAART) versus post-HAART era via meta-analysis.

230 aining highly active antiretroviral therapy (HAART) was 2.80 years (interquartile range, 1.73-5.92 ye

231 uired; highly active antiretroviral therapy (HAART) was discretionary.

232 hether highly active antiretroviral therapy (HAART) was included with the anti-tuberculosis regimen.

233 cribed highly active antiretroviral therapy (HAART), 21% were formerly on HAART, and 24% were HAART-n

234 use of highly active antiretroviral therapy (HAART), AIDS-related lymphoma remains common.

235 eiving highly active antiretroviral therapy (HAART), and HIV RNA was undetectable in the plasma of 75

236 ion of highly active antiretroviral therapy (HAART), cardiac mortality and morbidity were common in H

237 ction, highly active antiretroviral therapy (HAART), combines two or more drugs from at least two cla

238 after highly active antiretroviral therapy (HAART), compared with that for 10 HIV-seronegative subje

239 Before highly active antiretroviral therapy (HAART), congenital cytomegalovirus (CMV) rates were high

240 lowing highly active antiretroviral therapy (HAART), exposure to measles virus, and revaccination amo

241 ess to highly active antiretroviral therapy (HAART), lung disease remains common in human immunodefic

242 ithout highly active antiretroviral therapy (HAART), methods have varied, and results have not been c

243 essive highly active antiretroviral therapy (HAART), summarize the data on the detection and localiza

244 era of highly active antiretroviral therapy (HAART), the challenges that HIV/AIDS patients face with

245 als on highly active antiretroviral therapy (HAART), the epidemic burden continues to be high.

246 y used highly active antiretroviral therapy (HAART), though RT inhibitors offer generally a poor resi

247 era of highly active antiretroviral therapy (HAART), while it has emerged as a major public health pr

248 ted in highly active antiretroviral therapy (HAART)-treated HIV-infected subjects or in elite control

249 nd off highly active antiretroviral therapy (HAART).

250 als on highly active antiretroviral therapy (HAART).

251 rgoing highly active antiretroviral therapy (HAART).

252 cts on highly active antiretroviral therapy (HAART).

253 cts on highly active antiretroviral therapy (HAART).

254 ted on highly active antiretroviral therapy (HAART).

255 nce of highly active antiretroviral therapy (HAART).

256 act of highly active antiretroviral therapy (HAART).

257 ome of highly active antiretroviral therapy (HAART).

258 ext of highly active antiretroviral therapy (HAART).

259 ses to highly active antiretroviral therapy (HAART).

260 ion on highly active antiretroviral therapy (HAART).

261 before highly active antiretroviral therapy (HAART).

262 essing highly active antiretroviral therapy (HAART); however, the relative effects of these treatment

263 eiving highly active antiretroviral therapy (HAART); however, the safety and efficacy of such supplem

264 ory of highly active antiretroviral therapy (HAART; P < .001); and larger CRAE with lower CD4+ T lymp

265 iving highly active anti-retroviral therapy (HAART) or had clinical or laboratory evidence, or both,

266 74% on highly active antiretroviral therapy [HAART]) participants of a cohort with detailed character

267 These data support increased access to HAART and influenza vaccination for HIV-infected adults.

268 , single-item question measured adherence to HAART over the past 4 weeks.

269 asing retention in HIV care and adherence to HAART, and ultimately HIV suppression.

270 ences retention in HIV care and adherence to HAART, which in turn serve as key determinants of HIV su

271 ts on retention in HIV care and adherence to HAART.

272 naive from HAART, were randomly assigned to HAART with dietary intervention (diet group, n = 43) or

273 perinatally HIV-infected children exposed to HAART than in those of similar children from the pre-HAA

274 -infected women, comparisons were limited to HAART exposure status at conception, and those with simi

275 associated with increased HIV load prior to HAART (P=.005) and poor immune reconstitution following

276 virologic, but not immunologic, response to HAART was associated with increased risk of immune escap

277 s, or virologic and immunologic responses to HAART.

278 y of highly active antiretroviral treatment (HAART), a large proportion of human immunodeficiency vir

279 y by highly active antiretroviral treatment (HAART), HIV-1 is still not curable due to the persistenc

280 ring highly active antiretroviral treatment (HAART).

281 The independent effect of HIV under HAART on the oral microbiome was statistically significa

282 of a large sample of persons with HIV under HAART to an HIV-negative control group showed a complex

283 osition, including the presence of HIV under HAART.

284 ion demonstrates that HIV+ individuals under HAART presents a high prevalence of mild to moderate per

285 ants and 252 HIV-positive participants under HAART were sampled.

286 ty composition in HIV-positive persons under HAART to an HIV-negative group using 16S rRNA gene seque

287 Individuals with HIV undergoing HAART, compared with individuals without HIV, had no sta

288 in HIV-infected patients with KS undergoing HAART, KS improvement may be partly explained by immune

289 T), 21% were formerly on HAART, and 24% were HAART-naive.

290 ed mortality, which declines with widespread HAART introduction but does not disappear.

291 hrice-weekly throughout the study along with HAART in one of the groups.

292 inal arteriolar diameters is associated with HAART duration and viral load, and may reflect heightene

293 Diarrhea associated with HAART is typically caused by protease inhibitors (eg, ri

294 , diet prevents dyslipidemia associated with HAART.

295 therapeutics to be used in combination with HAART to slow or reverse this deterioration.

296 se reservoirs, when used in combination with HAART, could thus provide a strategy for the eradication

297 Differences improved with HAART, but still persisted up to 3 years after starting

298 rvention for HIV-1-infected individuals with HAART-related dyslipidemia, but there is no evidence fro

299 ted with no maternal HAART versus those with HAART (41% vs 6%; P < .05).

300 by treatment of tuberculosis with or without HAART.